Shares of Praxis Precision Medicines, Inc. (PRAX) are soaring 5.50% in intraday trading on Wednesday, following a positive initiation from Chardan Capital. The stock's significant jump comes as investors react to the new bullish stance from a respected research firm.
Chardan Capital has initiated coverage on Praxis Precision Medicines with a Buy rating, setting an ambitious price target of $80. This new target represents substantial upside potential from the stock's current trading levels, fueling investor optimism and driving the sharp increase in share price.
The positive sentiment from Chardan Capital aligns with the overall bullish view on Praxis Precision Medicines among Wall Street analysts. According to FactSet data, the company currently maintains an average rating of Buy from analysts, with a mean price target of $99.27. This consensus suggests that other analysts also see significant growth potential for the biopharmaceutical company, which specializes in developing therapies for central nervous system disorders.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。